Ignite Creation Date:
2025-12-24 @ 5:17 PM
Ignite Modification Date:
2025-12-27 @ 6:50 AM
Study NCT ID:
NCT04029350
Status:
UNKNOWN
Last Update Posted:
2019-08-21
First Post:
2019-07-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-07-31
Start Date Type:
ACTUAL
Primary Completion Date:
2020-01-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2021-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-07-21
First Submit QC Date:
None
Study First Post Date:
2019-07-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-08-19
Last Update Post Date:
2019-08-21
Last Update Post Date Type:
ACTUAL